The drugmaker's net profit fell 24% year-on-year to ₹20 crore, compared to ₹26 crore in the same period last year.
Revenue marginally rose by 1.4% to ₹163.4 crore from ₹161.2 crore in the base quarter.
EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) declined 10.2% to ₹25.4 crore, while the EBITDA margin slipped to 15.5% from 17.6% last year.
Lincoln Pharma shares are now trading 2.05% lower at ₹518.95. The stock is down 40% so far in 2025.
/images/ppid_59c68470-image-176302002882589234.webp)

/images/ppid_a911dc6a-image-177103853218557950.webp)


/images/ppid_a911dc6a-image-17710364781122582.webp)
/images/ppid_a911dc6a-image-177103642565816962.webp)
/images/ppid_a911dc6a-image-177103504309993710.webp)
/images/ppid_a911dc6a-image-177103508492594205.webp)


